2 weeks Ago By Defense World Staff
Prudential Financial Inc. increased its position in Globus Medical, Inc. (NYSE:GMED – Free Report) by 29.
6% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 15,906 shares of the medical device company’s stock after acquiring an additional 3,637 shares during the quarter. Prudential Financial Inc.
’s holdings in Globus Medical were worth $1,316,000 as of its most recent SEC filing. Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Coldstream Capital Management Inc.
increased its stake in shares of Globus Medical by 2.2% in the third quarter. Coldstream Capital Management Inc.
now owns 6,219 shares of the medical device company’s stock worth $447,000 after purchasing an additional 131 shares in the last quarter. First Horizon Advisors Inc. boosted its holdings in Globus Medical by 24.
7% in the 4th quarter. First Horizon Advisors Inc. now owns 666 shares of the medical device company’s stock worth $55,000 after buying an additional 132 shares during the period.
US Bancorp DE grew its stake in Globus Medical by 3.2% in the 4th quarter. US Bancorp DE now owns 4,305 shares of the medical device company’s stock valued at $356,000 after buying an additional 135 shares in the last quarter.
Berry Wealth Group LP raised its holdings in Globus Medical by 5.1% during the 4th quarter. Berry Wealth Group LP now owns 3,409 shares of the medical device company’s stock valued at $282,000 after acquiring an additional 164 shares during the period.
Finally, CIBC Asset Management Inc lifted its position in shares of Globus Medical by 5.3% during the fourth quarter. CIBC Asset Management Inc now owns 3,487 shares of the medical device company’s stock worth $288,000 after acquiring an additional 175 shares in the last quarter.
95.16% of the stock is currently owned by institutional investors. Insiders Place Their BetsIn other Globus Medical news, CFO Keith W.
Pfeil sold 14,167 shares of the business’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $88.29, for a total value of $1,250,804.
43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 18.
54% of the stock is owned by insiders. Globus Medical Stock PerformanceNYSE GMED opened at $69.01 on Friday.
Globus Medical, Inc. has a 52-week low of $49.33 and a 52-week high of $94.
93. The company has a fifty day moving average of $80.17 and a 200-day moving average of $80.
03. The company has a market capitalization of $9.49 billion, a P/E ratio of 92.
01, a P/E/G ratio of 1.61 and a beta of 1.19.
Globus Medical (NYSE:GMED – Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The medical device company reported $0.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.
74 by $0.10. The firm had revenue of $657.
29 million during the quarter, compared to analyst estimates of $646.19 million. Globus Medical had a return on equity of 10.
83% and a net margin of 4.09%. As a group, analysts forecast that Globus Medical, Inc.
will post 3.44 EPS for the current fiscal year. Analyst Ratings ChangesGMED has been the topic of a number of analyst reports.
StockNews.com lowered Globus Medical from a “buy” rating to a “hold” rating in a research note on Friday, March 21st. BTIG Research upped their price target on Globus Medical from $87.
00 to $91.00 and gave the company a “buy” rating in a research report on Thursday, December 12th. Wells Fargo & Company cut their price objective on shares of Globus Medical from $95.
00 to $93.00 and set an “overweight” rating for the company in a research report on Friday, February 21st. Roth Mkm upped their target price on shares of Globus Medical from $100.
00 to $115.00 and gave the stock a “buy” rating in a report on Tuesday, December 17th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Globus Medical in a research note on Tuesday, March 18th.
Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $97.
09.Read Our Latest Stock Analysis on GMEDGlobus Medical Profile (Free Report)Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.
Read MoreFive stocks we like better than Globus MedicalWhat is the Australian Securities Exchange (ASX) Conagra Stock Could Thrive as Tariffs Hit Other SectorsStock Splits, Do They Really Impact Investors?Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey FindsHow to Use the MarketBeat Excel Dividend CalculatorSpotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?.
